Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
688513
vs
S
Shanghai Composite
688513
Over the past 12 months, Chengdu Easton Biopharmaceuticals Co Ltd has underperformed Shanghai Composite, delivering a return of -30% compared to Shanghai Composite's 8% drop.
Stocks Performance
688513 vs Shanghai Composite
Performance Gap
688513 vs Shanghai Composite
Performance By Year
688513 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Chengdu Easton Biopharmaceuticals Co Ltd
Glance View
Chengdu Easton Biopharmaceuticals makes and sells biologic drugs, with a focus on recombinant protein medicines. These are medicines made by engineered cells rather than by simple chemical synthesis, and they are used in areas such as hospital treatment and specialty care. The company also works on the development and manufacturing steps needed to turn those proteins into approved prescription products. Its customers are mainly hospitals, medical institutions, and drug distributors that buy these medicines for patient care. Easton makes money by selling finished biopharmaceutical products, and its business depends on getting products approved, manufactured to strict quality standards, and supplied through the medical channel. What makes the company’s role distinct is that it sits in a technically demanding part of the drug industry. It is not just a drug seller; it has to handle research, cell-based production, purification, and quality control for complex biologic medicines. That gives it a place in the value chain where science, manufacturing, and regulation all matter at the same time.
